**Core Concept:** TNF (Tumour Necrosis Factor) is a pro-inflammatory cytokine that plays a crucial role in the immune response and inflammation. TNF-neutralizing agents are drugs that block the function of TNF, thereby reducing inflammation and its associated symptoms.

**Why the Correct Answer is Right:** **Correct Answer: D.**

D. Monoclonal Antibodies (e.g., infliximab) - These are laboratory-produced antibodies that specifically target and neutralize the activity of TNF. Infliximab is an example of a monoclonal antibody that binds to TNF and blocks its interaction with its receptors, leading to reduced inflammation and its symptoms.

**Why Each Wrong Option is Incorrect:**

A. **Option A (Etanercept):** Etanercept is a soluble receptor protein that binds to TNF and neutralizes its activity. It is a soluble TNF receptor fusion protein, which means it works differently from monoclonal antibodies and is therefore not a monoclonal antibody.

B. **Option B (Adalimumab):** Similar to etanercept, adalimumab is another monoclonal antibody that neutralizes TNF activity and is used to treat various inflammatory conditions.

C. **Option C (Rituximab):** Rituximab is a monoclonal antibody targeting CD20 (a cell surface protein on B cells), not TNF, indicating that it is not a TNF-neutralizing agent.

**Clinical Pearl / High-Yield Fact:** TNF-neutralizing agents like infliximab and adalimumab are used in the treatment of various inflammatory conditions, such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Their use is based on the understanding of TNF's role in inflammation and immune response.